- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in cancer immunotherapy 2019 – latest trends
Authors
Keywords
Immunotherapy, Programmed cell death protein 1 (PD-1), Programmed cell death protein ligand 1 (PD-L1), Chimeric antigen receptor T cells (CAR T cells), Trends, Regional distribution
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 38, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-06-19
DOI
10.1186/s13046-019-1266-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells
- (2019) Hongwei Du et al. CANCER CELL
- Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination
- (2019) Linda Hammerich et al. NATURE MEDICINE
- Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR
- (2019) Wingchi Leung et al. Cancer Immunology Research
- Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
- (2019) Elena Verzoni et al. Journal for ImmunoTherapy of Cancer
- Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
- (2018) Miriam Y. Kim et al. CELL
- Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
- (2018) Sarah B. Goldberg et al. CLINICAL CANCER RESEARCH
- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
- (2018) François-Xavier Danlos et al. EUROPEAN JOURNAL OF CANCER
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
- (2018) Nikolaos Zacharakis et al. NATURE MEDICINE
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab
- (2018) Adrien Costantini et al. OncoImmunology
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.
- (2018) Kathryn Cecilia Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squamous cell carcinoma.
- (2018) Richard Bryan Bell et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).
- (2018) Sean Matthew McBride et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.
- (2018) Tapan M. Kadia et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-related adverse events to predict survival in patients with advanced non-small cell lung cancer treated with nivolumab: A multicenter analysis.
- (2018) Biagio Ricciuti et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
- (2018) Sarwish Rafiq et al. NATURE BIOTECHNOLOGY
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Potential of CAR T Cell Therapy in Pancreatic Cancer
- (2018) Mehmet Akce et al. Frontiers in Immunology
- Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases
- (2018) Christine A. Garcia et al. Journal for ImmunoTherapy of Cancer
- 1213P_PRTolerance and efficacy of immune-checkpoint inhibitors for cancer in people living with HIV (PWHIV)
- (2018) A Gobert et al. ANNALS OF ONCOLOGY
- 1835PDComparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate/low
- (2018) M E Salem et al. ANNALS OF ONCOLOGY
- LBA37_PRNeoadjuvant ipilimumab plus nivolumab in early stage colon cancer
- (2018) M Chalabi et al. ANNALS OF ONCOLOGY
- 1141PDAssociation between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1
- (2018) M Kfoury et al. ANNALS OF ONCOLOGY
- LBA8_PRKEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
- (2018) B Burtness et al. ANNALS OF ONCOLOGY
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- 1363OEfficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC
- (2018) C Faivre-Finn et al. ANNALS OF ONCOLOGY
- Teaching an old dog new tricks: next-generation CAR T cells
- (2018) Nicholas Tokarew et al. BRITISH JOURNAL OF CANCER
- A Nobel Prize‐worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens
- (2018) Daniel M. Altmann IMMUNOLOGY
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
- (2018) Christian U. Blank et al. NATURE MEDICINE
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences
- (2017) Nikko Brix et al. IMMUNOLOGICAL REVIEWS
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma
- (2017) Nicolas Guibert et al. Oncotarget
- CAR T Cells Releasing IL-18 Convert to T-Bet high FoxO1 low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors
- (2017) Markus Chmielewski et al. Cell Reports
- Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis
- (2017) Rajeev K. Shrimali et al. Cancer Immunology Research
- Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
- (2017) Stephan Kruger et al. OncoImmunology
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
- (2016) J. Liu et al. Cancer Discovery
- Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model
- (2016) Nadia M. Luheshi et al. Oncotarget
- Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy
- (2016) Marine C C Raman et al. Scientific Reports
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy
- (2015) Shabnam Shalapour et al. NATURE
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
- (2015) Isaac Garcia-Murillas et al. Science Translational Medicine
- Is PD-L1 Expression a Biomarker of Response?
- (2015) Cancer Discovery
- PD-1 Restrains Radiotherapy-Induced Abscopal Effect
- (2015) S. S. Park et al. Cancer Immunology Research
- Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
- (2014) S. V. Hato et al. CLINICAL CANCER RESEARCH
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- The inducible caspase-9 suicide gene system as a “safety switch†to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells
- (2014) Tessa Gargett et al. Frontiers in Pharmacology
- Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma
- (2013) Markus Chmielewski et al. IMMUNOLOGICAL REVIEWS
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
- (2011) X. Frigola et al. CLINICAL CANCER RESEARCH
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer
- (2010) Mona Karlsson et al. ANNALS OF SURGICAL ONCOLOGY
- 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
- (2010) J. Vincent et al. CANCER RESEARCH
- Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
- (2009) W M Liu et al. BRITISH JOURNAL OF CANCER
- Immunogenic death of colon cancer cells treated with oxaliplatin
- (2009) A Tesniere et al. ONCOGENE
- Metinel Node—The First Lymph Node Draining a Metastasis—Contains Tumor-Reactive Lymphocytes
- (2008) Kjell Dahl et al. ANNALS OF SURGICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started